Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
暂无分享,去创建一个
A. d’Arminio Monforte | F. Ceccherini‐Silberstein | G. Ippolito | M. Capobianchi | A. De Luca | C. Torti | E. Giombini | G. Rozera | G. Cassola | A. Castagna | I. Abbate | A. Cozzi Lepri
[1] S. Subramaniam,et al. Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus , 2015, Retrovirology.
[2] A. d’Arminio Monforte,et al. Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy , 2013, The Journal of antimicrobial chemotherapy.
[3] L. Vandekerckhove,et al. Frequency and Predictors of HIV-1 Co-receptor Switch in Treatment Naive Patients , 2013, PloS one.
[4] P. Harrigan,et al. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] F. Ceccherini‐Silberstein,et al. The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing , 2013, PloS one.
[6] P. Narciso,et al. Ultra‐deep sequencing reveals hidden HIV‐1 minority lineages and shifts of viral population between the main cellular reservoirs of the infection after therapy interruption , 2012, Journal of medical virology.
[7] P. Narciso,et al. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[8] G. D'offizi,et al. Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection , 2011, AIDS.
[9] B. Gazzard,et al. The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] V. Calvez,et al. Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years , 2011, AIDS.
[11] J. Izopet,et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists , 2010 .
[12] Andrew J. Low,et al. Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and “Deep” Sequencing to Plasma RNA and Proviral DNA , 2010, Journal of acquired immune deficiency syndromes.
[13] G. D'offizi,et al. Comparison of real-time PCR methods for measurement of HIV-1 proviral DNA. , 2010, Journal of Virological Methods.
[14] L. Stuyver,et al. HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays , 2010, AIDS research and therapy.
[15] E. Poveda,et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. , 2010, The Journal of antimicrobial chemotherapy.
[16] G. Angarano,et al. Co‐receptor switch during HAART is independent of virological success , 2009, Journal of medical virology.
[17] A. d’Arminio Monforte,et al. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Giovanni Chillemi,et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations , 2009, Retrovirology.
[19] R. González-González,et al. Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. , 2007, The Journal of antimicrobial chemotherapy.
[20] V. Calvez,et al. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART , 2007, AIDS.
[21] E. Poveda,et al. Prevalence of X4 tropic HIV‐1 variants in patients with differences in disease stage and exposure to antiretroviral therapy , 2007, Journal of medical virology.
[22] L. Ruiz,et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. , 2007, The Journal of antimicrobial chemotherapy.
[23] Christophe Pasquier,et al. Population-Based Sequencing of the V3 Region of env for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies , 2007, Journal of Clinical Microbiology.
[24] Eoin Coakley,et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] Thomas Lengauer,et al. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[26] David W. Williamson,et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. , 2006, The Journal of infectious diseases.
[27] Christophe Pasquier,et al. R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.
[28] John P. Moore,et al. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.
[29] S. Philpott. HIV-1 coreceptor usage, transmission, and disease progression. , 2003, Current HIV research.
[30] H. Schuitemaker,et al. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. , 1999, The Journal of infectious diseases.
[31] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[32] H. Schuitemaker,et al. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. , 1996, The Journal of infectious diseases.
[33] D. Richman,et al. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.
[34] I. Keet,et al. Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.
[35] Huisman,et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.